Antiangiogenesis therapy in the treatment of metastatic colorectal cancer

Axel F Grothey, Carmen Allegra

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many cancers, including metastatic colorectal cancer (mCRC). The growth and metastasis of primary tumors is dependent upon their ability to acquire and maintain an adequate blood supply; however, angiogenesis in tumors is an irregular process leading to chaotic and hyperpermeable vessels that may result in increased intratumoral pressure and poor exchange of macromolecules and oxygen. It has been hypothesized that inhibition of angiogenesis in tumors can both impair the formation of new tumor blood vessels and possibly 'normalize' the existing tumor vasculature, causing a more efficient delivery of cytotoxic chemotherapies (CTs). Over the last decade, therapies that target vascular endothelial growth factor (VEGF) have become a component of treatment for several cancers. In particular, the combination of bevacizumab with established chemotherapeutic regimens for mCRC has been shown to improve overall and progression-free survival, as well as response rates, over CT alone. Agents that target various members of the VEGF family, as well as signaling by the VEGF receptors and their tyrosine kinase components, are currently under development and evaluation in clinical trials. Integration of these new therapies into the treatment of mCRC will ultimately increase the available therapeutic options for patients. Still, many challenges remain, including identifying and validating relevant biomarkers to guide the optimal use of antiangiogenesis agents.

Original languageEnglish (US)
Pages (from-to)301-319
Number of pages19
JournalTherapeutic Advances in Medical Oncology
Volume4
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Colorectal Neoplasms
Neoplasms
Vascular Endothelial Growth Factor A
Therapeutics
Vascular Tissue Neoplasms
Drug Therapy
Vascular Endothelial Growth Factor Receptor
Protein-Tyrosine Kinases
Disease-Free Survival
Blood Vessels
Biomarkers
Clinical Trials
Oxygen
Neoplasm Metastasis
Pressure
Growth

Keywords

  • Aflibercept
  • antiangiogenesis
  • bevacizumab
  • biomarker
  • clinical trials
  • metastatic colorectal cancer
  • regorafenib

ASJC Scopus subject areas

  • Oncology

Cite this

Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. / Grothey, Axel F; Allegra, Carmen.

In: Therapeutic Advances in Medical Oncology, Vol. 4, No. 6, 11.2012, p. 301-319.

Research output: Contribution to journalArticle

Grothey, Axel F ; Allegra, Carmen. / Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. In: Therapeutic Advances in Medical Oncology. 2012 ; Vol. 4, No. 6. pp. 301-319.
@article{63f5556719484036b0f1a844227dea42,
title = "Antiangiogenesis therapy in the treatment of metastatic colorectal cancer",
abstract = "The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many cancers, including metastatic colorectal cancer (mCRC). The growth and metastasis of primary tumors is dependent upon their ability to acquire and maintain an adequate blood supply; however, angiogenesis in tumors is an irregular process leading to chaotic and hyperpermeable vessels that may result in increased intratumoral pressure and poor exchange of macromolecules and oxygen. It has been hypothesized that inhibition of angiogenesis in tumors can both impair the formation of new tumor blood vessels and possibly 'normalize' the existing tumor vasculature, causing a more efficient delivery of cytotoxic chemotherapies (CTs). Over the last decade, therapies that target vascular endothelial growth factor (VEGF) have become a component of treatment for several cancers. In particular, the combination of bevacizumab with established chemotherapeutic regimens for mCRC has been shown to improve overall and progression-free survival, as well as response rates, over CT alone. Agents that target various members of the VEGF family, as well as signaling by the VEGF receptors and their tyrosine kinase components, are currently under development and evaluation in clinical trials. Integration of these new therapies into the treatment of mCRC will ultimately increase the available therapeutic options for patients. Still, many challenges remain, including identifying and validating relevant biomarkers to guide the optimal use of antiangiogenesis agents.",
keywords = "Aflibercept, antiangiogenesis, bevacizumab, biomarker, clinical trials, metastatic colorectal cancer, regorafenib",
author = "Grothey, {Axel F} and Carmen Allegra",
year = "2012",
month = "11",
doi = "10.1177/1758834012454464",
language = "English (US)",
volume = "4",
pages = "301--319",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Antiangiogenesis therapy in the treatment of metastatic colorectal cancer

AU - Grothey, Axel F

AU - Allegra, Carmen

PY - 2012/11

Y1 - 2012/11

N2 - The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many cancers, including metastatic colorectal cancer (mCRC). The growth and metastasis of primary tumors is dependent upon their ability to acquire and maintain an adequate blood supply; however, angiogenesis in tumors is an irregular process leading to chaotic and hyperpermeable vessels that may result in increased intratumoral pressure and poor exchange of macromolecules and oxygen. It has been hypothesized that inhibition of angiogenesis in tumors can both impair the formation of new tumor blood vessels and possibly 'normalize' the existing tumor vasculature, causing a more efficient delivery of cytotoxic chemotherapies (CTs). Over the last decade, therapies that target vascular endothelial growth factor (VEGF) have become a component of treatment for several cancers. In particular, the combination of bevacizumab with established chemotherapeutic regimens for mCRC has been shown to improve overall and progression-free survival, as well as response rates, over CT alone. Agents that target various members of the VEGF family, as well as signaling by the VEGF receptors and their tyrosine kinase components, are currently under development and evaluation in clinical trials. Integration of these new therapies into the treatment of mCRC will ultimately increase the available therapeutic options for patients. Still, many challenges remain, including identifying and validating relevant biomarkers to guide the optimal use of antiangiogenesis agents.

AB - The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many cancers, including metastatic colorectal cancer (mCRC). The growth and metastasis of primary tumors is dependent upon their ability to acquire and maintain an adequate blood supply; however, angiogenesis in tumors is an irregular process leading to chaotic and hyperpermeable vessels that may result in increased intratumoral pressure and poor exchange of macromolecules and oxygen. It has been hypothesized that inhibition of angiogenesis in tumors can both impair the formation of new tumor blood vessels and possibly 'normalize' the existing tumor vasculature, causing a more efficient delivery of cytotoxic chemotherapies (CTs). Over the last decade, therapies that target vascular endothelial growth factor (VEGF) have become a component of treatment for several cancers. In particular, the combination of bevacizumab with established chemotherapeutic regimens for mCRC has been shown to improve overall and progression-free survival, as well as response rates, over CT alone. Agents that target various members of the VEGF family, as well as signaling by the VEGF receptors and their tyrosine kinase components, are currently under development and evaluation in clinical trials. Integration of these new therapies into the treatment of mCRC will ultimately increase the available therapeutic options for patients. Still, many challenges remain, including identifying and validating relevant biomarkers to guide the optimal use of antiangiogenesis agents.

KW - Aflibercept

KW - antiangiogenesis

KW - bevacizumab

KW - biomarker

KW - clinical trials

KW - metastatic colorectal cancer

KW - regorafenib

UR - http://www.scopus.com/inward/record.url?scp=84871879404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871879404&partnerID=8YFLogxK

U2 - 10.1177/1758834012454464

DO - 10.1177/1758834012454464

M3 - Article

C2 - 23118806

AN - SCOPUS:84871879404

VL - 4

SP - 301

EP - 319

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 6

ER -